Ultragenyx Pharmaceutical | RARE - Cash And Equivalent

Stock Price
24.04
Daily Change
0.25 1.05%
Monthly
-0.66%
Yearly
-46.99%
Q1 Forecast
23.33

Ultragenyx Pharmaceutical reported $202.51M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 847.02M 85.02M Sep/2025
Agios Pharmaceuticals USD 92.71M 11.84M Sep/2025
Alnylam Pharmaceuticals USD 1.49B 376.56M Sep/2025
BioMarin Pharmaceutical USD 1.25B 36.29M Sep/2025
Insmed USD 334.76M 949.56M Sep/2025
Ionis Pharmaceuticals USD 2.24B 1.94B Sep/2025
Kyowa Hakko Kirin JPY 234.6B 20.23B Jun/2025
MacroGenics USD 80.13M 50.56M Sep/2025
Moderna USD 1.13B 147M Sep/2025
Neurocrine Biosciences USD 340.2M 76.2M Sep/2025
PTC Therapeutics USD 672.62M 344.77M Sep/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Sarepta Therapeutics USD 613.08M 102.48M Sep/2025
Ultragenyx Pharmaceutical USD 202.51M 36.4M Sep/2025
Vertex Pharmaceuticals USD 6.29B 95.8M Sep/2025